fbpx Skip to main content

Public Policy Newsletter Article

Biocom Policy Work, Policy Events Continue to be Guided by COVID-19

  • 2020-08-27T15:00:00.000+0000
  • Author: Jimmy Jackson

This month, Biocom started an exciting new COVID-19 virtual briefing series designed for policy makers and their staffs. The first session provided an overview of how the industry has engaged on COVID-19, including a poignant opening by moderator Assemblymember Autumn Burke, a recovered COVID-19 patient herself, followed by excellent discussions by executives of Biocom members Eli Lilly & Co. and Novartis. More information on this series can be found here.

In noteworthy regional news, on September 9th Biocom will host the next in its “Return to Work” series, this session focused on the needs of Bay Area companies. Industry professionals and consultants will share best practices for facility and EH&S managers and discuss some of the unique challenges life science companies are facing as they resume and increase operations. In San Diego, Biocom will be hosting a life science forum with mayoral candidates Barbara Bry and Todd Gloria on September 17th. More information on that event here. And, you can read about these and Biocom’s other regional activities here.

In federal news, as more trial data comes in and companies, who have pivoted countless scientists and large amounts of resources in the fight against COVID-19, move closer to filing for FDA approval, some have begun to argue that the federal government should exercise “march in rights” under the authority of the Bayh-Dole Act. Biocom has been a leader among the state life science associations to educate Congress and the Administration on why this would be a misreading of the Act, and recently co-signed a letter with 35 other state associations to HHS Secretary Azar explaining this. Learn more about this effort here.

Biocom is constantly monitoring proposed federal rules and guidances for their potential effect on our members, then issuing comment where appropriate. CMS is currently soliciting comment on its proposed 2021 CMS Medicare Physician Fee Schedule and Quality Payment Program, which include expansions of telehealth and other topics of interest to Biocom members. Click here for more information on how you might help Biocom engage on this subject.